Eleven Biotherapeutics, Inc.
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011
Total Revenue 1,334 - -
Cost of Revenue - - -
Gross Profit 1,334 - -
Operating Expenses
Research and Development 13,788 15,263 9,411
Sales, General and Admin. 4,024 4,213 3,267
Non-Recurring Items - - -
Other - - -
Operating Income (16,478) (19,476) (12,678)
Income From Continuing Operations
Add'l Income/Expense Items (147) (13) 3
Earnings Before Interest and Tax (16,625) (19,489) (12,675)
Interest Expense 1,400 168 151
Earnings Before Tax (18,025) (19,657) (12,826)
Income Tax - - -
Minority Interest - - -
Equity Earnings Unconsolidated Subsidiary - - -
Net Income Cont. Operations (18,025) (19,657) (12,826)
Non Recurring Events
Discontinued Operations - - -
Extraordinary Items - - -
Effect of Accounting Changes - - -
Other Items - - -
Net Income (18,025) (19,657) (12,826)
Preferred Stock and Other Adjustments (3,857) (3,111) (1,452)
Net Income Applicable to Common Shareholders (21,882) (22,768) (14,278)